Genesis Research and Development, which in July abandoned plans to merge with an unlisted Australian company, is seeking legal advice and will make an announcement on its future amid a lack of funds to continue operating.
The company had its shares halted from trading on the NZX and ASX pending a statement.
In its notice to the ASX, it says the trading halt will end "when legal advice is received and an announcement is made about the future of the company due to the lack of funds for ongoing costs".
The company suspended operations in May 2010 and laid off its entire staff.
In July this year it placed 9.1 million shares, which it said gave it enough funds to remain listed while it considers further investments.
The shares last traded at 1.8 cents, valuing the company at $980,000, and have declined 40% in the past year.
In July, Genesis called off a proposed merger with Australia-based Mariposa Health, an unlisted public pharmaceutical development company.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- Dairy farmers need to reconsider 'smart level' of debt, Feds dairy chairman Hoggard says
- Credit card spending has dived in UK post-Brexit: Mastercard exec
- Accountant pinged for unauthorised car payments, conflicts of interest
- Brexit aftermath: disdain, the elites, and the warning for conservative parties everywhere
- US Democrats vote not to oppose TPP
Most listened to
- NBR's Rob Hosking and John Shewan discuss the just released report
- Queenstown mayoral candidate Jim Boult talks up his chances
- Nathan Smith on the unsurprising US Democrat support of the TPP
- Mercer's Garry Adams sees upside in expats' cost of living drop
- What Australia needs now is stability, no more hopping around, says CPA CEO Alex Malley